Morgan Stanley Maintains Embecta(EMBC.US) With Sell Rating, Maintains Target Price $13
BTIG Maintains Embecta(EMBC.US) With Hold Rating
BTIG Reaffirms Their Hold Rating on Embecta Corporation (EMBC)
Morgan Stanley Maintains Embecta(EMBC.US) With Sell Rating, Raises Target Price to $13
Recommendation to Sell: Anticipated Costs and Competition Challenge Embecta's New Pump Program
Analysts Conflicted on These Healthcare Names: Healthequity (HQY) and Embecta Corporation (EMBC)
BTIG Remains a Hold on Embecta Corporation (EMBC)
Embecta Analyst Ratings
Morgan Stanley Maintains Underweight on Embecta, Lowers Price Target to $12
Morgan Stanley Lowers Price Target on Embecta to $12 From $13, Maintains Underweight Rating
Damo: Maintaining the Embecta (EMBC.US) rating, adjusted from reduced holdings to reduced holdings rating, and adjusted the target price from $16.00 to $13.00.
Embecta Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)
Analysts Offer Insights on Healthcare Companies: McKesson (MCK), Embecta Corporation (EMBC) and Abbott Labs (ABT)
Analysts Offer Insights on Healthcare Companies: Embecta Corporation (EMBC), Mettler-Toledo (MTD) and Humacyte (HUMA)
Morgan Stanley Adjusts Price Target on to $16 From $15, Maintains Underweight Rating
Morgan Stanley Maintains Underweight on Embecta, Raises Price Target to $16
Embecta Analyst Ratings
Embecta Corporation (EMBC) Receives a Hold From BTIG
Analysts Offer Insights on Technology Companies: Cognizant (CTSH), Embecta Corporation (EMBC) and SolarEdge Technologies (SEDG)